Buccolam
midazolam
Epilepsy
Date of authorisation:
Revision: 19
Last updated:
MedicineHumanAuthorised
Akynzeo
netupitant
palonosetron
Vomiting
Neoplasms
Nausea
Cancer
Date of authorisation:
Revision: 17
Last updated:
MedicineHumanAuthorised
Aloxi
palonosetron
Vomiting
Cancer
Date of authorisation:
Revision: 22
Last updated:
MedicineHumanAuthorised
Nasolam and associated names - referral
midazolam
Article 29(4) referrals
Status: European Commission final decision
Opinion/position date:
EC decision date:
Last updated:
ReferralHuman
Palonosetron Hospira
palonosetron
Nausea
Vomiting
Cancer
Date of authorisation:
Revision: 4
Last updated:
MedicineHumanWithdrawn
EMEA-001198-PIP03-17-M04 - paediatric investigation plan
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Other
PIP number: P/0272/2020
Route(s) of administration: Intravenous use
Pharmaceutical form(s):
Powder for concentrate for solution for infusion
Concentrate for solution for infusion
Decision date:
Last updated:
Compliance check: ✖
PIPHuman
EMEA-001198-PIP02-16 - paediatric investigation plan
Decision type: RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)
Therapeutic area: Other
PIP number: P/0358/2016
Route(s) of administration: Intravenous use
Pharmaceutical form(s):
Powder for solution for infusion
Decision date:
Last updated:
Compliance check: ✖
PIPHuman
EMEA-000395-PIP01-08 - paediatric investigation plan
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Neurology
PIP number: P/155/2009
Route(s) of administration: Oromucosal use
Pharmaceutical form(s):
Oromucosal solution
Decision date:
Last updated:
Compliance check: ✔
PIPHuman